Neuronal apoptosis inhibitory protein is implicated in amyotrophic lateral sclerosis symptoms

Osamu Kano1, Kazunori Tanaka2, Takuya Kanno3, Yasuo Iwasaki1 & Joh-E Ikeda4,5,6,7

The delineation of the molecular pathology underlying amyotrophic lateral sclerosis (ALS) is being hampered by the lack of suitable biomarkers. We have previously reported that bromocriptine upregulates the endogenous antioxidative factor, neuronal apoptosis inhibitory protein (NAIP), sustains motor function and slows disease progression in ALS patients, implying the NAIP's implication in ALS. Here, we aimed to verify a correlation of NAIP level with disease progression in ALS patients. The amount of NAIP in mononuclear cells (MNC) from peripheral blood from ALS patients (n = 18) and the age matched healthy controls (n = 12) was validated by NAIP-Dot blotting. Notably, the MNC-NAIP level in ALS patients (0.62 ± 0.29 ng) was nearly half of that in the healthy controls (1.34 ± 0.61 ng, P = 0.0019). Furthermore, the MNC-NAIP level in ALS patients and their ALS Functional Rating Scale-Revised (ALSFRS-R) score were evaluated through 1 year. Regression analysis of the MNC-NAIP vs ALSFRS-R indicated that a higher amount of MNC-NAIP was associated with a smaller change in ALSFRS-R at 12 months (R² = 0.799; P = 0.016), suggesting that a progressive increment of the MNC-NAIP led to slower ALS progression. Our present report implies that NAIP will have broad implications for ALS symptoms as a risk factor and a promising prognostic biomarker.
of these compounds alleviated disease progression in an ALS (SOD1 H46R) and (SOD1 G93A) mouse models.

serve as an easily accessible prognostic biomarker. observed in ALS patients with rapid disease progression. Thus, our study strongly suggests that MNC-NAIP may level retained motoneuronal function to some extent up to 12 months testing period, but no such retention was factor for ALS. Furthermore, we found that ALS patients who exhibited longitudinal increases in the MNC-NAIP level from peripheral blood. We further longitudinally evaluated the relationship between the MNC-NAIP level and performed dot blot analysis with anti-NAIP antiserum using whole protein extract of mononuclear cells (MNC) phonuclear leukocytes. Hence, to measure the amount of NAIP in both ALS patients and healthy controls, we human peripheral hematopoietic cells, particularly in mononuclear cells, but not in erythrocytes and polymor -

binding-oligomerization domain and leucine-rich repeat (NLR) protein. Recent findings have reported that in vivo have shown that upregulated and overexpressed NAIP protects neuronal cells from oxidative injuries in vitro and in vivo. NAIP, which is thought to be a modifier gene for spinal muscular atrophy, is a founding member of the inhibitor of apoptosis. NAIP has also been classified as a nucleotide binding-oligomerization domain and leucine-rich repeat (NLR) protein. Recent findings have reported that NAIP plays a crucial role in the host defense against bacterial infection, and also forms a multiprotein complex with NLRC4 (NLR family, CARD domain containing 4) to induce inflammasome activation via bacterial infection. Importantly, NAIP selectively suppresses the cell death induced by oxidative stress. In fact, studies have shown that upregulated and overexpressed NAIP protects neuronal cells from oxidative injuries in vitro and in vivo. Hence, NAIP is thought to be a multifunctional protein.

Given the action of NAIP against oxidative stress, we previously established a NAIP-ELISA-based drug screening system for the development of novel ALS drugs. Accordingly, we identified the NAIP-upregulated small molecule compound L-745,870 as a drug candidate for antipsychotic treatment, bromocriptine mesylate (BRC) as a Parkinson’s disease drug, and WN1316 as a drug candidate for ALS. Indeed, the post-onset administration of these compounds alleviated disease progression in an ALS (SOD1) and (SOD1) mouse models. Interestingly, clinical research showed that the motoneuronal function in ALS patients was sustained in part by the BRC treatment. As BRC is an NAIP-upregulating compound, we hypothesized that the NAIP level might be low in ALS patients, in comparison with that in healthy controls, and may recover in ALS patients to a certain extent following BRC treatment.

In this study, we assessed whether the NAIP levels change in ALS patients. Most tissues and cells (except for hematopoietic tissues) express NAIP at very low levels. In the present study, NAIP expression was noted in human peripheral hematopoietic cells, particularly in mononuclear cells, but not in erythrocytes and polymorphonuclear leukocytes. Hence, to measure the amount of NAIP in both ALS patients and healthy controls, we performed dot blot analysis with anti-NAIP antiserum using whole protein extract of mononuclear cells (MNC) from peripheral blood. We further longitudinally evaluated the relationship between the MNC-NAIP level and ALSFRS-R up to 12 months as an indicator of disease progression. We found that the MNC-NAIP level was markedly low in ALS patients less than half amount of the healthy control, suggesting that NAIP may serve as a risk factor for ALS. Furthermore, we found that ALS patients who exhibited longitudinal increases in the MNC-NAIP level retained motoneuronal function to some extent up to 12 months testing period, but no such retention was observed in ALS patients with rapid disease progression. Thus, our study strongly suggests that MNC-NAIP may serve as an easily accessible prognostic biomarker.

**Results**

**Baseline characteristics of ALS patients and healthy controls.** In the present study, we aimed to assess the change in MNC-NAIP, ALSFRS-R, and %FVC in 18 sporadic ALS patients during the 12 months testing period. Among them, 6 patients were followed up to 12 months. On the other hands, 3 patients died within the testing period, 3 could not visit our clinic at fixed testing intervals, and 6 discontinued after participating in edaravone clinical study. Therefore, the rest of 12 ALS patients were followed for <12 months.

The populations of ALS patients and healthy controls in the present study were similar in terms of age at baseline (64.1 years vs. 59.8 years), but different in gender (Table 1). The clinical characteristics of each ALS patient, including ALSFRS-R; %FVC; and riluzole, PEG, and NIV use, are summarized in Supplementary Table S1.

|                          | ALS (n = 18) | Control (n = 12) |
|--------------------------|-------------|----------------|---|
| age, year (SD)           | 64.1 (12.3) | 59.8 (11.9)   |
| male/female, n           | 13/5        | 4/8            |
| clinical onset, n (%)    | 6 (33.3)    | 9 (50.0)       |
| bulbar                   | 3 (16.7)    | 27.6 (16.3)    |
| upper limb               | 37.1 (7.4)  | ALSFRS-R score |
| lower limb               | 77.3 (27.5) | forced vital capacity, % (SD) |
| duration months (SD)     | 18 (100)    | 11 (61.1)      |
| riluzole, n (%)          | 7 (38.9)    | NIV, n (%)      |
| PEG, n (%)               |             |                |
| n (%)                    |             |                |

Table 1. Summary of the demographic and baseline characteristics. ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, PEG: percutaneous endoscopic gastrostomy, NIV: noninvasive ventilation, n: number, SD: standard deviation.
MNC-NAIP levels in ALS patients are lower than those of healthy controls at baseline. First, to analyze the NAIP expression in MNC, polymorphonuclear cells, and erythrocytes, we performed Western blotting with anti-NAIP antiserum. In addition, we detected specific MNC-NAIP expression in peripheral blood (Supplementary Fig. S1). Next, to evaluate the amount of MNC-NAIP at baseline, we conducted dot blotting and quantitated per μg of whole protein extract of MNC from 18 ALS patients and 12 healthy controls (n = 4 technical replicates; Fig. 1A). The MNC-NAIP levels in healthy controls and in ALS patients ranged from 0.66 to 2.35 ng/μg (average, 1.34 ± 0.61 ng/μg) and from 0.28 to 1.43 ng/μg (average, 0.62 ± 0.29 ng/μg), respectively (Fig. 1B). We have also statistically analyzed the data excepting 3 healthy control high outliers and NAIP levels in ALS patients still significantly decreased compared with the healthy controls (P = 0.0018). When we compared the gender difference in each group, the average MNC-NAIP levels in male (n = 13) and female (n = 5) ALS patients were 0.71 ± 0.29 ng/μg and 0.40 ± 0.14 ng/μg, respectively. In that of healthy male (n = 4) and female (n = 8) controls were 1.77 ± 0.66 ng/μg and 1.12 ± 0.49 ng/μg, respectively. Some gender difference was observed in ALS patients (P = 0.04), but the difference between ALS patients and healthy control male and female groups were P = 0.04 in male, and P < 0.01 in female. Hence, there was no correlation between the MNC-NAIP level and age, clinical onset, disease duration, PEG/NIV use in both the healthy controls and ALS patients (Supplementary Table S1). These results suggest that the MNC-NAIP levels were markedly lower in ALS patients than in healthy controls. Moreover, we examined the MNC-NAIP levels in Japanese with Parkinson’s disease, and the NAIP level in MNC from Parkinson’s disease patients was as high as that of healthy controls (average, 0.91 ± 0.46 ng/μg). 8 of 11 patients were being treated with the dopamine agonist (as shown in Supplementary Table S1), therefore the effect of polypharmacy cannot be excluded.

Longitudinal ALS progression and change in the MNC-NAIP level. To determine whether the amount of MNC-NAIP was correlated with ALS progression, we longitudinally evaluated the NAIP level in MNC from ALS patients by dot blotting and assessed the correlation between the MNC-NAIP levels and the ALSFRS-R/%FVC ratio. In case A9, A10, A11, and A12, an increment of the MNC-NAIP level was observed between baseline and 12 months (Figs 1A and 2C–F, Supplementary Table S1), and the amount of MNC-NAIP at 12 months ranged from 0.71 to 1.78 ng/μg (the MNC-NAIP level at 12 months was 1.8 to 2.4-fold greater than that at baseline level; Supplementary Table S1). The longitudinal increase of MNC-NAIP showed no significant change or slight reduction of the ALSFRS-R score and %FVC in these 4 ALS patients (Fig. 2C). Interestingly, a significant increase in MNC-NAIP revealed no change of ALSFRS-R score and % FVC (Fig. 2C).

Although the MNC-NAIP level was found to have increased at 12 months (0.58 ng/μg; a 2.1-fold increase as compared to the baseline level; Supplementary Table S1) in case A8 (who showed bulbar type at clinical onset), the ALSFRS-R score and %FVC had reduced during the 12 months testing period (Fig. 2B). Furthermore, in 6 ALS patients, including case A7 (testing period up to 12 months), case A1 (testing period up to 8 months), and
cases A2, A6, A13, and A15 (testing period up to 4 months), the MNC-NAIP level showed almost no change or indicated a slight decrease (0.45–0.72 ng/μg; less than 1.1-fold) as compared to the baseline level (Supplementary Table S1). The steady or slight decrease in MNC-NAIP was accompanied by a marked decrease of ALSFRS-R score and %FVC (Fig. 2A,B and Supplementary Table S1). These results imply that an increment of MNC-NAIP to a critical amount is capable to reduce ALS symptoms.

Regression analysis between the change in MNC-NAIP and ALSFRS-R. To further verify the correlation between the amount of NAIP and the rate of change in the ALSFRS-R score, we performed a detailed examination of the regression statistics of the results (Supplementary Table S1). We observed a significant correlation between the amount of MNC-NAIP and the rate of change in the ALSFRS-R at 12 months (P = 0.016; R² = 0.798; Fig. 3B). Moreover, the rate of change of the amount of MNC-NAIP was also correlated with the rate of change in the ALSFRS-R at 4 and 12 months (Fig. 3C,D). Thus, we observed a correlation between the MNC-NAIP level and ALS progression, indicating that the cumulative MNC-NAIP level led to the slow progression of ALS.

Discussion

The cause and pathogenesis of ALS remain unclear, and many of the ALS drug candidates tested, excluding riluzole and edaravone, have not shown any apparent outcome in the past decade. The lack of a reliable biomarker in ALS is hampering the delineation of molecular pathogenesis and the development of therapeutics for ALS.

A previous ALS biomarker study assessed oxidative stress biomarkers, including coenzyme Q10, in clinical trials in ALS patients; however, negative results were obtained.30,31 Other studies reported that creatinine and serum C-reactive protein could serve as biomarkers for survival.32–34 Moreover, a recent study showed that the cerebrospinal fluid (CSF) levels of neurofilament light chain (NFL)—a marker of axonal loss—were markedly higher in ALS patients as compared to the healthy controls. In spite of the relatively constant level of NFL level during follow-up period, NFL is a potential prognostic biomarker of ALS.35

In the present study, we focused on the endogenous antioxidative factor NAIP to explore a novel ALS biomarker, and accordingly examined the longitudinal change in the NAIP level in MNC from the peripheral blood of ALS patients. We observed that the MNC-NAIP level at baseline in ALS patients was lower than nearly half that of the healthy controls. In addition, ALS patients with a longitudinal and cumulative amount of the NAIP in MNC during the testing period showed a correlation with slow disease progression. Although the sample size is small, our study shows that the change in the MNC-NAIP level is directly or inversely associated with ALS progression.

Oxidative stress is thought to be one of the pathogenetic mechanisms for ALS.39 Moreover, NAIP selectively suppresses oxidative stress-induced cell death in vitro and in vivo, and the overexpression of NAIP protects neuron and axonal regeneration.23–25 Furthermore, a previous study demonstrated that treatment with NAIP-upregulating compound BRC sustains motoneuronal function in ALS patients.29 NAIP upregulation...
protects motoneurons via suppression of microglia IL-1β generation and gliosis in ALS mice23. In the present study, we observed slow disease progression in ALS patients with cumulative/longitudinal increases in MNC-NAIP levels. Thus, NAIP might protect against motoneuronal dysfunction and neuronal inflammation via suppression of inflammatory factor production (including IL-1β) induced by oxidative stress; however, we have no evidence regarding the manner in which the NAIP level in MNC reflects that in glia cells and motoneuronal cells at this moment and it remains to be ruled out.

NAIP is a particularly well-characterized protein that is part of the NLR subfamily and constitutes parts of NLRC4 inflammasome, and plays a role in innate immunity36. In ALS and inflammasome research, increased inflammasome activation appears to be involved in ALS37. Moreover, inflammasome activity is known to be regulated by reactive oxygen species (ROS)38. In the present study, we found that the NAIP level was approximately 50% lower in ALS patients than in healthy controls. Therefore, the reduction of NAIP at baseline in ALS patients may facilitate oxidative stress-induced damage, which may lead to ROS generation and consequently to the induction of inflammasome activation. These background events may lead to the chronic neuronal inflammation that triggers the onset of ALS. Thus, NAIP possesses an antinomic dual nature, which are protection of

Figure 3. Regression analysis of MNC-NAIP levels and ALSFR-R. Eleven ALS patients at 4 months (case A1, A2, A6–A13, and A15) and 6 ALS patients at 12 months (Case A7–A12) were chosen for the evaluation of regression analysis. Correlations between the amount of MNC-NAIP and the rate of change in ALSFRS-R at 4 months (A) and 12 months (B) and between the rate of change in the amount of MNC-NAIP and the rate of change in ALSFRS-R at 4 months (C) and 12 months (D) are shown.

Figure 4. Model depicting the dual nature of NAIP. In normal neuronal cells: NAIP protects these cells against neuronal inflammation/dysfunction through the suppression of inflammatory factor production (including IL-1β) induced by oxidative stress. In damaged neuronal cells: NAIP commits the NLRC4 inflammasome complex, and induces IL-1β activation, resulting in induction of inflammation/dysfunction in motor neuron.
neuronal cells against oxidative stress on one hand and facilitation of inflammatory-induced cell death leading to apoptosis/necrosis to exclude damaged motoneuronal cells on the other hand (Fig. 4).

In the present study, we sought to address the following queries. First, we verified whether the change of the MNC-NAIP level was unique to ALS. To address this issue, we analyzed the MNC-NAIP levels in patients with Parkinson’s disease, and the NAIP level in MNC from Parkinson’s disease patients was as high as that of healthy controls, implying that the change of the MNC-NAIP level is not quite common to PD and could be neither for neurodegenerative disorders. Secondly, we considered from which stage the NAIP level was decreased in ALS patients. As shown in Table S1, it appears that there is no correlation between the disease duration of more or less than 2 years and the MNC-NAIP level at baseline. Additionally, weak correlation between the amount of MCN-NAIP and the change of ALSFRS-R score revealed at 4 months testing period (Fig. 3A; \( R^2 = 0.1197, P = 0.29 \)), but NAIP upregulation shown as the change of the rate of NAIP amount indicated a reliable commitment to slow ALS progression even at 4 months testing period (Fig. 3C; \( R^2 = 0.30767, P = 0.07 \)). Apparently, a correlation between the higher amount of NAIP and the slowing ALS progression became obvious at 12 months testing period (Fig. 3B; \( R^2 = 0.79892, P = 0.016 \)). Furthermore, as all the participants were taking riluzole, but not edaravone, the entire course of our study, the treatment regimen was identical in all the ALS participants. Hence, we speculate that the effect of polypharmacy was extremely low. Therefore, the decrease in the NAIP level may initiate at the early stage of ALS or pre-symptomatic stage. Thirdly, we contemplated the mechanism underlying the longitudinal NAIP increase in the MNC. It has been reported that more inflammation related-gene expression are detected in monocytes in rapidly progressing rather than slower progressing ALS patients. Considering that the previous studies suggested the link between inflammatory response and oxidative stress in ALS and NAIP expression was detected in MNC specifically (Supplementary Fig. S1), it is conceivable that MNC-NAIP is being upregulated by the signal released from the neuronal cell undergoing apoptosis/necrosis via NLRC4 inflammasome activation, and suppresses dominantly neuronal inflammation in healthy neural environment. Cumulative chronic inflammation breaches the healthy neural environment, and NLRC4 inflammasome activation turns to dominant to leading the neuronal degeneration and death.

On the other hand, the bulb type in ALS is generally thought to result in rapid progression as compared to the limb type. In the present study, the ALSFRS-R score was decreased, particularly in the bulb type, despite an increase in the MNC-NAIP level. This trend may be related to the severe neuronal inflammation which exceed the NAIP protection against motoneuronal dysfunction. Our present study also showed that a few healthy volunteer controls (C4-6) exhibited MNC-NAIP levels that were almost twice as high as the other controls. With regards to this different levels, transient or persistent NAIP-upregulation may have occurred as a result of a hidden cancer or some other inflammatory causes.

In conclusion, to our knowledge, this is the first study to show that the MNC-NAIP level is low in ALS patients. Although the mechanism underlying the reduction of the NAIP level in peripheral blood MNC of ALS patients remains elusive, our data suggest that a lower NAIP level may be a risk factor for ALS. In addition, we observed a correlation between the cumulative expression of NAIP and the slowing of ALS progression, although in the small group analysis of the patients. These findings implying a role for NAIP as an ALS prognostic biomarker should be braced up by further large scale clinical study. Thus, our present study provides novel insights into the molecular pathogenesis of ALS. The development of strategies targeting the NAIP alteration in ALS patients may be useful as an evaluation and monitoring system for identifying novel ALS therapy.

Methods

Participants and sampling. This study was conducted between September 1, 2013, and December 31, 2015 on 18 Japanese ALS patients who met the revised El Escorial diagnostic criteria for definite, probable, and probable laboratory-supported ALS. Healthy controls typically included spouses and unrelated caregivers. Clinical information was obtained at 4 month intervals up to 12 months. Symptom onset was defined as the first patient-reported weakness. The progression rate was calculated at baseline and at visits every 4 months using ALSFRS-R and forced vital capacity (%FVC). Taking of riluzole, induction of percutaneous endoscopic gastrostomy (PEG), and noninvasive ventilation (NIV) at the time of sampling was recorded. ALSFRS-R provides a physician-generated estimated of the patient’s degree of functional impairment, which can be evaluated serially to objectively assess any response to treatment or progression of disease. This score includes 12 questions that ask the physician to rate the patient’s level of functional impairment (speech, salivation, swallowing, handwriting, cutting food, dressing and hygiene, turning in bed, walking, climbing stairs, dyspnea, orthopnea, respiratory insufficiency). Each task is rated on a five-point scale from 0 = can’t do, to 4 = normal ability. Individual item scores are summed to produce a reported score of between 0 = worst and 48 = best.

Antibody. With regard to the primary antibodies for Western blotting, anti-CD11b antibody (1:500, Assay Biotech), anti-CD16-β (Z64) mouse monoclonal IgG2b (1:200, Santa Cruz Biotechnology), anti-GAPDH (14C10) rabbit mAb (1:10000, Cell Signaling Technology), and anti-β-actin antibody (1:3000, Cell Signaling Technology) were used.

Anti-NAIP antiserum (1:5000, Neugen Pharma Inc.), which is commercially available (Wako, product code 019-24251), was raised by immunizing Japanese White rabbit with full-length NAIP synthesized using cell-free protein synthesis (WEPRO1240G Expression Kit) according to the manufacturer’s instruction, and was used as the primary antibody for both Western blotting and dot blotting.
Anti-rabbit IgG, horseradish peroxidase (HRP)-linked whole antibody (1:10000, GE Healthcare) and anti-mouse IgG, HRP-linked whole antibody (1:10000, GE Healthcare) were used as secondary antibodies.

**Isolation of mononuclear cells from human peripheral blood.** To measure the NAIP levels, peripheral blood MNC were isolated from human venous blood by density centrifugation. Five milliliters of the anticoagulated venous blood were carefully layered over 5 mL of Polymorphrep (Axis-Shield) in a 15-ml polystyrene conical tube. The tubes were centrifuged at 500 × g for >30 min using a swing-out rotor at room temperature. A Pasteur-pipette was inserted into the separated upper and lower bands, which consisted of MNC and polymorphonuclear cells, respectively; cells from each band were carefully harvested and suspended with an equal volume of 2-fold diluted PBS (Takara Bio Inc.). Thereafter, the cell suspension was mixed with an equal volume of PBS, and centrifuged at 400 × g for 10 min at room temperature. After discarding the supernatant, the cells were resuspended with PBS and centrifuged at 400 × g for 10 min at room temperature; the supernatant was again discarded. When residual erythrocytes were detected in the collected-cell fraction, the contaminating erythrocytes were lysed by incubating the collected-cell fraction in 5 mL of ice-cold distilled water for 30 s, followed by the addition of an equal volume of 20 mM Hepes buffer (pH7.4) containing 1.8% (w/v) NaCl. After centrifugation at 400 × g for 10 min at room temperature, the supernatant was discarded. Cells were resuspended with 5 mL (MNC) or 4 mL (polymorphonuclear cells) of PBS, and the cell numbers were counted by Luna (LogosBiosystems) according to the manufacturer’s instruction. After centrifugation at 400 × g for 10 min at room temperature and discarding the supernatant, cells were mixed with 1 mL of PBS and transferred to a 1.5 mL tube. After another session of centrifugation at 400 × g for 10 min at room temperature and discarding the supernatant, the cells were stored at −80 °C until further use.

Approximately 100 μL of erythrocytes was suspended with an equal volume of 2-fold diluted PBS, and the cell suspension was mixed with an equal volume of PBS. After centrifugation at 400 × g for 10 min at room temperature and discarding the supernatant, the cells were stored at −80 °C until further use.

**Preparation of protein extract from MNC, polymorphonuclear cells, and erythrocytes.** Frozen cells were suspended in M-PER mammalian protein extraction reagent (Thermo Fisher Scientific) supplemented with Protease Inhibitor Cocktail for Use with Mammalian Cell and Tissue Extracts (Nacalai Tesque), and lysed by incubation for 30 min on ice. Cell lysates were centrifuged at 14,000 × g for 15 min at 4 °C, and the supernatant was collected as protein extract. The protein concentration was determined using a Pierce 660 nm Protein Assay kit (Thermo Fisher Scientific) and bovine serum albumin as a protein standard according to the manufacturer’s instructions.

**Western blotting.** From the protein extract, 1 μg protein from MNC, 5 μg protein from polymorphonuclear cells, and 10 μg protein from erythrocytes were separated on 5–20% SDS-polyacrylamide gel (ATTO) and transferred onto a polyvinylidene difluoride (PVDF) membrane (Bio-Rad). Membranes were blocked with Blocking-One reagent (Nacalai Tesque) for 1 h at room temperature, and were incubated with the appropriate primary antibody in Can Get Signal solution 1 (TOYOBO) for 3–4 h at room temperature or overnight at 4 °C. Membranes were washed with TBST (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% [w/v] Tween20) 5 times for 5 min each, and then incubated with the HRP-conjugated secondary antibody in Can Get Signal solution 2 (TOYOBO) for 1 h at room temperature. After washing with TBST (3 times for 5 min each), signals were detected using Immobilon Western HRP substrate (Millipore) and were exposed on an X-ray film.

**Dot blotting.** Proteins from healthy controls and ALS patients were diluted with PBS containing 0.001% (w/v) Ponceau S staining solution (Nacalai Tesque) to a concentration of 0.05 μg/μL. NAIP recombinant protein at 10 different concentrations (0–12.8 ng/20 μL) was prepared by diluting with PBS containing 0.001% (w/v) Ponceau S as the standard solution. Twenty microliters of the protein solutions and standard solutions were applied on the same PVDF membrane (11 × 7.5 cm) (Bio-Rad) set in a 96-well dot blot apparatus (DHM-96, Scie-Plas Ltd.) and were aspirated for 30 s using a vacuum pump. Membrane was dried for 1 h at room temperature. Four sets of membranes were prepared, with the same protein amount on each membrane. After the PVDF membranes were rehydrated with methanol for 30 s and washed in TBST for 10 min, they were blocked with Blocking-One reagent (Nacalai Tesque) for 1 h at room temperature and then incubated with the anti-NAIP antiserum in Can Get Signal Solution 1 (TOYOBO) overnight at 4 °C. After washing with TBST 3 times for 10 min each, PVDF membranes were incubated with HRP-conjugated secondary anti-rabbit IgG (GE Healthcare) in Can Get Signal Solution 2 (TOYOBO) for 1 h at room temperature. After washing with TBST 3 times for 10 min each, the PVDF membranes were then treated with Immobilon Western HRP Substrate (Millipore) for 5 min, and the signals of each dot were visualized using an Amersham Imager 600 (GE Healthcare). The density of each dot was measured using ImageQuant TL analysis software (GE Healthcare). The amount of NAIP was calculated using a NAIP recombinant protein standard curve.

**Regression analysis.** We performed regression analysis using JMP® version 13.0.0 (SAS Institute Inc.). The parameter of the rate of change of ALSFRS-R was calculated using the following formula: (Initial ALSFRS-R score at baseline) − (ALSFRS-R score at 4 or 12 months)/(Initial ALSFRS-R score at baseline) × 100. The parameter of the rate of change of NAIP was calculated using the following formula: (Initial amount of NAIP at 4 or 12 months) − (Initial amount of NAIP)/(Initial amount of NAIP at baseline) × 100.

**Statistical analysis.** Statistical analyses were performed with JMP® version 13.0.0 (SAS Institute Inc.). Numerical variables are expressed as mean ± standard deviation (SD). We used 2-tailed t-tests and nonparametric Mann-Whitney U test or Pearson’s chi-square test for group comparisons, as appropriate. A P value < 0.05 was considered statistically significant.
39. Zhao, W. et al. Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes. *JAMA Neurol* 74, 677–685, https://doi.org/10.1001/jamaneurol.2017.0357 (2017).
40. Liu, Y., Hao, W., Dawson, A., Liu, S. & Fassbender, K. Expression of amyotrophic lateral sclerosis-linked SOD1 mutant increases the neurotoxic potential of microglia via TLR2. *J. Biol. Chem.* 284, 3691–3699, https://doi.org/10.1074/jbc.M804432200 (2009).
41. Brooks, B. R., Miller, R. G., Swash, M. & Munsat, T. L. World Federation of Neurology Research Group on Motor Neuron. D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. *Amyotroph. Lateral Scler. Other Motor Neuron Disord.* 1, 293–299 (2000).

**Acknowledgements**

We are very grateful for a part of these grants: Grant-in Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science and Technology (O.K. 15K08368), the Adaptable and Seamless Technology Transfer Program through Target-driven R&D (A-STEP) from the Japan Science and Technology Agency (J.I.). We thank all patients and their family members. In addition, special thanks to Ken Ikeda, Kiyokazu Kawabe, Yuji Kawase, Takanori Takazawa, Takehisa Hirayama, Kiyoko Murata, Ken Miura, Yuichi Ishikawa, Masaru Yanagihashi, Junpei Nagasawa, Maya Kyuzen, Masahiro Sawada, Sayori Hanashiro, Junya Ebina, Harumi Morioka, Shigeko Kawai, Tomoko Matsumoto, Masami Yamashita, and Kaori Yasutake who contributed the clinical research including the cares of the patients.

**Author Contributions**

O.K., K.T., K.I. and J.I. contributed to the study design, and revision of the manuscript. Data were collected and analyzed by T.K., K.T. and O.K. O.K. and Y.I. created the figures. O.K. contributed to committee for assessment at registration of all patients. All authors were involved in the writing of the report.

**Additional Information**

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-18627-w.

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017